Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 03/28/17 | 8-K | Current report filing |
|
13 | |
| 03/17/17 | EFFECT | Notice of Effectiveness |
|
1 | |
| 03/15/17 | 8-K | Current report filing |
|
4 | |
| 03/10/17 | POS AM | Post-effective amendment to a registration statement that is not immediately effective upon filing |
|
4 | |
| 02/15/17 | 8-K | Current report filing |
|
4 | |
| 01/25/17 | 3 | Initial statement of beneficial ownership of securities |
|
1 | |
| 01/17/17 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
7 | |
| 01/17/17 | 8-K | Current report filing |
|
7 | |
| 01/13/17 | 424B3 | Prospectus filed pursuant to Rule 424(b)(3) |
|
5 | |
| 01/13/17 | 8-K | Current report filing |
|
4 |
